Back to Search
BRIGITTE WIDEMANN, M.D.
M.D.
Pediatric Hematology & Oncology Physician
NPI: 1407130362Individual
Specialties, Licenses & Credentials
Pediatric Hematology & Oncology PhysicianPrimary
Pediatrics — Pediatric Hematology-Oncology
Code: 2080P0207X
D0054838(MD)
Research & Publications (20)
Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2.
PMID 19671848·Clin Cancer Res·2009
7-preclinical
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
PMID 19508838·Curr Oncol Rep·2009
6-review
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors.
PMID 19075272·J Clin Oncol·2009
3-trial
Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
PMID 16421428·J Clin Oncol·2006
3-trial
Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2.
PMID 15494606·J Natl Cancer Inst·2004
8-other
High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
PMID 15139068·Cancer·2004
1-meta
Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid.
PMID 10945838·J Pharmacol Exp Ther·2000
7-preclinical
Characteristics and outcome of pediatric patients enrolled in phase I oncology trials.
PMID 18586923·Oncologist·2008
8-other
Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
PMID 18559970·Neuro Oncol·2008
8-other
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors.
PMID 18281544·Clin Cancer Res·2008
3-trial
The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression.
PMID 18071635·J Neurooncol·2008
8-other
Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.
PMID 17959855·Blood·2008
3-trial
Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.
PMID 17509460·Pediatr Neurol·2007
3-trial
NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight.
PMID 17215493·Neurology·2007
8-other
A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors.
PMID 16914576·Clin Cancer Res·2006
3-trial
Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group.
PMID 16408203·Cancer Chemother Pharmacol·2006
3-trial
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors.
PMID 16234526·J Clin Oncol·2005
3-trial
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 8906 BRADMOOR DR
BETHESDA, MD 20817 - Phone
- (301) 496-7387
Quick Facts
- NPI
- 1407130362
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile